Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 2/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | G6PD | P11413 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.38 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21643853 | 0.81 | PDGFRB (0.41) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL21643832 | 0.81 | PDGFRB (0.43) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL23590866 | 0.80 | PDGFRB (0.45) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL9084161 | 0.79 | PKM (0.44) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL13280353 | 0.79 | TDP1 (0.47) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL15996997 | 0.78 | PDGFRB (0.51) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL8064653 | 0.78 | PDGFRB (0.48) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL15122867 | 0.78 | SIRT6 (0.45) | GPR35PDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL14809433 | 0.77 | MEN1 (0.48) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL12000739 | 0.76 | TDP1 (0.49) | GPR35PDGFRBFGFR1PDGFRAFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129267-B2 | Heteroaryl amide compounds as sting activators | INCYTE CORPORATION (US) | 2024-10-29 | — | — | US | disclosed |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | INCYTE CORPORATION | 2023-12-14 | — | — | US | disclosed |
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | INCYTE CORPORATION (US) | 2023-03-07 | — | — | US | disclosed |
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | INCYTE CORPORATION (US) | 2023-03-07 | — | — | US | disclosed |
| US-11427597-B2 | Heteroaryl amide compounds as sting activators | INCYTE CORPORATION (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220056049-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | INCYTE CORPORATION | 2022-02-24 | — | — | US | disclosed |
| US-20210163493-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | INCYTE CORPORATION | 2021-06-03 | — | — | US | disclosed |
| US-20210163493-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | INCYTE CORPORATION | 2021-06-03 | — | — | US | disclosed |
| US-10875872-B2 | Heteroaryl amide compounds as sting activators | INCYTE CORPORATION (US) | 2020-12-29 | — | — | US | disclosed |
| US-10875872-B2 | Heteroaryl amide compounds as sting activators | INCYTE CORPORATION (US) | 2020-12-29 | — | — | US | disclosed |
| WO-2020146237-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | INCYTE CORPORATION (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020028566-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | INCYTE CORPORATION (US) | 2020-02-06 | — | — | WO | disclosed |
| US-20200039994-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | INCYTE CORPORATION | 2020-02-06 | — | — | US | disclosed |
| US-20200039994-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | INCYTE CORPORATION | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129267-B2 | Heteroaryl amide compounds as sting activators | STING1, MAVS, IRF3 | GPR35 702/4885PDGFRB 742/4885FGFR1 3628/4885 |
| US-20220056049-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | STING1, MAVS, IRF3 | GPR35 702/4885PDGFRB 742/4885FGFR1 3628/4885 |
| US-11596692-B1 | PD-L1/STING conjugates and methods of use | STING1, PDCD1LG2, CD274 | GPR35 2870/4885PDGFRB 861/4885FGFR1 2086/4885 |
| US-20230398225-A1 | PD-L1/STING CONJUGATES AND METHODS OF USE | STING1, PDCD1LG2, CD274 | GPR35 2870/4885PDGFRB 861/4885FGFR1 2086/4885 |
| US-10875872-B2 | Heteroaryl amide compounds as sting activators | STING1, MAVS, IRF3 | GPR35 702/4885PDGFRB 742/4885FGFR1 3628/4885 |
| US-11427597-B2 | Heteroaryl amide compounds as sting activators | STING1, MAVS, IRF3 | GPR35 702/4885PDGFRB 742/4885FGFR1 3628/4885 |
| US-20210163493-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | STING1, MAVS, IRF3 | GPR35 702/4885PDGFRB 742/4885FGFR1 3628/4885 |
| US-20200039994-A1 | HETEROARYL AMIDE COMPOUNDS AS STING ACTIVATORS | STING1, MAVS, IRF3 | GPR35 702/4885PDGFRB 742/4885FGFR1 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.